 | | Vol. 12.36 – 17 September, 2020 |
| |
|
|
| Scientists report that expression of the immune checkpoint molecule B7-H4 was prevalent among immune-cold TNBC, where its expression inversely correlated with that of PD-L1.
[Cancer Discovery] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Studies in three mouse models of breast cancer identified profound discrepancies between cell-autonomous and systemic Akt1- or Akt2-inducible deletion on breast cancer tumorigenesis and metastasis.
[Molecular Cell] |
|
|
|
| Investigators report a CD44 and scavenger receptor class B1 dual-targeting hyaluronic acid nanoparticle loaded with the near-infra-red fluorescent dye DiR-BOA for sentinel lymph nodes imaging in breast cancer.
[Light: Science & Applications] |
|
|
|
| Researchers report that CD47-mediated anti-phagocytosis was concurrently upregulated with HER2 in radioresistant breast cancer (BC) cells and cancer radiotherapy-treated mouse syngeneic BC.
[Nature Communications] |
|
|
|
| Scientists revealed that TET2 played a pivotal role in mammary gland development and luminal lineage commitment.
[Nature Communications] |
|
|
|
| Investigators report that PIK3CA C-terminal mutations occured at a low frequency across multiple cancer subtypes, including breast, and was sufficient to drive oncogenic transformation in vitro and in vivo.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Using the recently established culturing method that allowed propagation of normal and cancerous breast epithelial cells of luminal origin, flow cytometry characterization, and genomic sequencing, scientists showed that cancer cells were detected in breast milk.
[Cancer Research] |
|
|
|
| Investigators showed that novel combinations of JAK2 inhibitors with SMO inhibitors synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells.
[Oncogene] |
|
|
|
| Using multiple human breast cancer cell lines, the osteogenic cocktail model was established in vitro to demonstrate calcification-exacerbated metastasis.
[British Journal of Cancer] |
|
|
|
| The analysis of transcriptome sequencing implied that activation of STAT3 signaling pathway by downregulated miR-337-3p might be a potential mechanism to induce epithelial to mesenchymal transition (EMT) of cancer cells and promote metastasis under chronic stress
[Cell Death & Disease] |
|
|
|
| To determine potential biomarkers of palbociclib sensitivity to assist in patient selection and clinical development, scientists investigated the effects of palbociclib in a panel of molecularly characterized breast cancer cell lines.
[Cell Death & Disease] |
|
|
|
| Researchers used high‐throughput single‐cell RNA‐seq data to investigate the role of long non‐coding RNAs (lncRNAs) using the hierarchical model of mammary epithelium.
[Stem Cells] |
|
|
|
|
| The authors focus on the functions of long noncoding RNAs (lncRNAs) in breast cancer invasion and metastasis, with particular emphasis on the functional properties, the regulatory factors, the therapeutic promise, as well as the future challenges in studying these lncRNA.
[Cell Death & Disease] |
|
|
|
| Investigators summarize the role of peroxisome proliferator-activated receptor gamma (PPARγ) activation in breast cancer focusing on the underlying cellular and molecular mechanisms involved in the regulation of cell proliferation, cell cycle, and cell death, in the modulation of motility and invasion as well as in the cross-talk with other different signaling pathways.
[Cancers] |
|
|
|
| The authors address the effect of malignant cells, adjuvant therapies and patient-specific factors that may influence the success of regenerative strategies using adipose derived stromal cells (ADSCs) for post cancer tissue regeneration.
[Stem Cell Reviews and Reports] |
|
|
|
|
| The companies globally developed and commercialized Seattle Genetics’ ladiratuzumab vedotin which was currently in Phase II clinical trials for breast cancer and other solid tumors. Separately, Seattle Genetics granted Merck an exclusive license to commercialize TUKYSA® for the treatment of HER2-positive cancers.
[Seattle Genetics, Inc.] |
|
|
|
| Translational Research in Oncology announced enrolment of the first patient in a Phase II randomized, multi-center, open-label clinical trial of GDC-9545 sponsored by F. Hoffmann-La Roche.
[Translational Research in Oncology (GlobeNewswire, Inc.)] |
|
|
|
| ProFound AI™ Risk was the first and only commercially available clinical decision support tool that provided an accurate two-year breast cancer risk estimation that was personalized for each woman, based solely on a screening mammogram. The technology, which allowed for the detection of cancers between screenings, was clinically proven to significantly outperform existing breast cancer risk models.
[iCAD, Inc.] |
|
|
|
|
|
|
|
| | University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| | The Research Institute of the McGill University Health Centre – Montreal, Quebec, Canada |
|
|
|
| | German Cancer Research Center – Heidelberg, Germany |
|
|
|
| | University of Cambridge – Cambridge, United Kingdom |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
